Compare
NAVs as of 20 Aug 2026
Add a second fund to compare. Until then every figure below is shown against the ELSS median (66 funds), which is the only comparison one fund can support.
Growth of ₹100 (rebased over the selected window)
Common period 03 Apr 2006 – 20 Aug 2026. Every series is rebased to ₹100 at the start of this window. Benchmark lines are the category index WealthTicker measures against, which is not always the benchmark the scheme itself declares — the fund page’s Scheme Info names that one. Nifty 500 history starts 25 Jul 2016, so that benchmark is not plotted over this window — pick a shorter range to see it.
View as table
| Date | Franklin India ELSS Tax Saver Fund |
|---|---|
| 03 Apr 2006 | ₹100.00 |
| 14 Dec 2007 | ₹104.41 |
| 26 Aug 2009 | ₹72.37 |
| 08 May 2011 | ₹77.08 |
| 17 Jan 2013 | ₹83.23 |
| 30 Sep 2014 | ₹103.21 |
| 11 Jun 2016 | ₹105.95 |
| 21 Feb 2018 | ₹109.77 |
| 04 Nov 2019 | ₹106.35 |
| 16 Jul 2021 | ₹125.50 |
| 28 Mar 2023 | ₹113.40 |
| 08 Dec 2024 | ₹188.99 |
| 20 Aug 2026 | ₹157.24 |
| Metric | Franklin Templeton · Regular · IDCW NAV ₹61.09 Very High risk ★☆☆☆☆ | Category median ELSS · 66 funds |
|---|---|---|
| -8.97% | +1.19% | |
| +5.11% | +8.64% | |
| +4.64% | +7.82% | |
| +3.32% | +9.60% | |
| +2.25% | +8.99% | |
| +2.84% | — | |
| +4.66% | +10.48% | |
| +4.43% | +10.98% | |
| +4.23% | +8.21% | |
| Risk | ||
| 15.10% | 14.15% | |
| -0.09 | 0.21 | |
| -0.12 | 0.29 | |
| -67.44% | -39.29% | |
| Nifty 500 | — | |
| -6.17% | -2.44% | |
| 0.99 | 0.95 | |
| 88.6% | 85.5% | |
| 124.0% | 95.8% | |
| 1.91% | 2.37% | |
| ₹6,082Cr | ₹694.87Cr | |
| None | — | |
| 3 years | — | |
| ₹500 | — | |
| ₹500 | — | |
| 3% | 34% | |
| R Janakiraman · 10.3y | — | |
| 03 Apr 2006 | — | |
| 47 | — | |
| 46.5% | — | |
| 5.3% | — | |
Best marks the strongest value in a row, and only where the gap is bigger than noise — a near-tie is left unmarked rather than dressed up as a result. SIP XIRR is a ₹10,000/month instalment over 5 years of real NAV history. Nothing here is supplied by a fund house. For research only — not investment advice.